Insight Wealth Strategies LLC Has $5.46 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Insight Wealth Strategies increased its Regeneron stake by 26.9% in the second quarter, bringing its holdings to 8,734 shares valued at approximately $5.46 million. Institutional investors and hedge funds collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with EPS of $14.29 and revenue of $4.29 billion, beating estimates and marking 16.7% year-over-year revenue growth. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $797.75.
• Despite positive momentum in Eylea HD, Dupixent and the broader pipeline, investors face risks from a securities class-action lawsuit tied to a failed melanoma trial and an approximately $11 billion market-capitalization loss; a director also sold $130,030 of stock under a Rule 10b5-1 plan.

Insight Wealth Strategies LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 26.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,734 shares of the biopharmaceutical company's stock after acquiring an additional 1,850 shares during the quarter. Insight Wealth Strategies LLC's holdings in Regeneron Pharmaceuticals were worth $5,456,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. WPG Advisers LLC boosted its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $26,000. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $29,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $31,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, signaling continued confidence in the company’s business and pipeline prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Positive Sentiment: Recent analysis highlighted continued strength in Eylea HD and Dupixent, along with oncology growth and pipeline progress. The stock has risen 21.9% over the past month, although the sharp advance may also increase profit-taking risk. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio, but the figures also contain an undefined percentage change and appear unreliable. Consequently, the data provides no meaningful indication of short-covering or bearish positioning.
• Negative Sentiment: Several law firms, including Pomerantz, Gross, Faruqi & Faruqi, and Hagens Berman, are promoting or reminding investors about a securities class action against Regeneron. The litigation follows disclosures that a Phase 3 melanoma therapy trial failed, an event reportedly associated with an approximately $11 billion market-capitalization loss. The legal notices themselves do not establish wrongdoing, but they add reputational and potential financial-risk concerns. Investors covered by the proposed class period may face a September 14, 2026 lead-plaintiff deadline. REGN Investor Alert

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company's stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research report on Thursday, July 9th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a "hold" rating in a research note on Wednesday, July 29th. Citigroup raised their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research note on Monday, August 3rd. Finally, Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $797.75.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $797.00 on Wednesday. The company has a market cap of $82.06 billion, a PE ratio of 19.70, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The firm has a 50-day moving average of $665.31 and a 200-day moving average of $713.04. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the prior year, the firm earned $12.81 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source